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ABSTRACT:
The ribosomal P70 S6 kinases play a crucial role in PI3K/mTOR regulated 
signalling pathways and are therefore potential targets for the treatment of a variety 
of diseases including diabetes and cancer. In this study we describe the identification 
of three series of chemically distinct S6K1 inhibitors. In addition, we report a novel 
PKA-S6K1 chimeric protein with five mutations in or near its ATP-binding site, which 
was used to determine the binding mode of two of the three inhibitor series, and 
provided a robust system to aid the optimisation of the oxadiazole-substituted 
benzimidazole inhibitor series. We show that the resulting oxadiazole-substituted 
aza-benzimidazole is a potent and ligand efficient S6 kinase inhibitor, which blocks 
the phosphorylation of RPS6 at Ser235/236 in TSC negative HCV29 human bladder 
cancer cells by inhibiting S6 kinase activity and thus provides a useful tool compound 
to investigate the function of S6 kinases.
INTRODUCTION 
The 70 KDa ribosomal S6 kinases (S6K) RPS6KB1 
(S6K1) and RPS6KB2 (S6K2) are key effectors of PI3K/
mTOR-regulated signalling, and have been implicated 
in a variety of human diseases including diabetes and 
cancer [1-5]. They belong to the family of AGC kinases 
and are highly homologous with a sequence identity of 
83% in their catalytic domains [6]. S6K1, which is the 
most extensively studied of the two, has been shown to 
phosphorylate a number of substrates that regulate protein 
synthesis, including the 40S ribosomal protein S6 (RPS6), 
and proteins involved in translation, such as the eukaryotic 
initiation factor 4B (EIF4B) and eukaryotic elongation 
factor 2 kinase [7].
In turn, S6K1 is activated by phosphorylation of 
the activation loop residue Thr252 (S6K1 numbering) by 
PDK1, and by phosphorylation of Thr412, located in the 
kinase extension region. Phosphorylation of Thr412 is 
achieved by mTORC1, which is a heterotrimeric complex 
comprising mTOR, raptor and mLST-8 [1]. However, for 
full activation of S6K1, these phosphorylation events have 
to be preceded by phosphorylation of a series of serine and 
threonine residues in the C-terminal autoinhibitory domain 
and by phosphorylation of Ser394 in the turn-motif [8].
The identification of S6K1 as a potential therapeutic 
target in oncology is supported by the fact that the S6K1 
gene (RPS6KB1) is located at human chromosome 
17q23, a region that is amplified in 20% of primary 
breast cancers as measured by comparative genomic 
hybridisation [9]. In addition, increased expression of 
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S6K1 has been associated with cell transformation and 
elevated proliferation rates in tumours [10, 11]. Moreover, 
amplification and overexpression of S6K1 have been 
linked with poor prognosis and an increased risk of local 
recurrence [12]. Studies in cultured cells have confirmed 
that S6K activity is enhanced by mechanisms activating 
the PI3-kinase/Akt/mTOR pathway, such as loss of the 
tumour suppressor PTEN, and have shown a positive 
correlation between S6K activity and tumour growth 
[13]. In addition, loss of either of the tumour suppressive 
TSC1/2 complex proteins can result in activation of 
mTORC1 and S6K. The TSC2 protein acts as a GTPase-
activating protein (GAP) towards Rheb (Ras homologue 
enriched in brain) and promotes conversion of active 
Rheb-GTP into the inactive form, Rheb-GDP, that can 
no longer stimulate mTORC1 [14]. Furthermore, S6K1 
regulates the turnover of the oncogenic protein MDM2 in 
the ovarian cancer cell line OVCAR-3 [15]. In DU-145 
prostate cancer cells, S6K1 increased survivin expression 
produced by upstream activation of the pathway, whereas 
acute ablation of endogenous S6K1 by small interfering 
RNA down-regulated survivin levels [16]. Finally, 
increased phosphorylation of S6K and corresponding 
phosphorylation of RPS6 was observed in HPV16-infected 
cervical cancer tissue samples [17], and the constitutive 
activation of S6K1 is associated with cisplatin resistance 
in human H69 small cell lung cancer cells [18].
Ribosomal S6 kinases are thus interesting 
therapeutic targets for cancer treatment. In this study we 
describe a high-throughput screening (HTS) campaign 
against S6K1 using an amplified luminescent proximity 
homogeneous assay, and the subsequent hit evaluation for 
the three hit series we identified. In addition, we report 
a novel PKA-S6K1 chimeric protein, which was used to 
elucidate the binding mode of two of the HTS hit series 
including the improved C-6-substituted azabenzimidazole 
S6K inhibitors. Finally, for the most potent compound 
from the azabenzimidazole series we demonstrate 
inhibition of S6K in intact human bladder tumour cells 
exhibiting loss of expression of the TSC1/2 complex. 
RESULTS AND DISCUSSION
A PKA-S6K1 Chimera for Structure-Based Drug 
Design.
To date, the available structural data for S6 kinases 
are limited to three crystal structures of the S6K1 kinase 
domain. Two structures are of unphosporylated S6K1 and 
consistent with an inactive state of the kinase. The third 
is of S6K1 phosphorylated on Thr252 in the activation 
loop and consistent with a partially activated state of the 
kinase [19]. The three crystal structures of S6K1 were 
solved as protein-ligand complexes with the pan-kinase 
inhibitor staurosporine, but the authors were not able to 
generate an apo-S6K1 structure, which they attributed to 
a susceptibility of the apo-enzyme to aggregation upon 
concentration and upon storage. Whilst the published 
S6K1 crystal structures provided an exciting first 
structural insight in S6 kinases, the crystal system might 
be less applicable to iterative protein-ligand structural 
studies informing the structure-based design of potent S6K 
inhibitors.
In order to generate a more robust crystal system 
suitable for the generation of high-resolution protein-
ligand structural data required to facilitate S6K inhibitor 
design, we decided to develop a S6K1 chimeric protein 
based on the catalytic subunit of the closely related 
AGC kinase PKAα (PKA). Chimeric proteins based on 
PKA have been successfully used in the discovery of 
PKB inhibitors [20, 21], the analysis of Aurora kinase 
inhibitors [22], and to study the selectivity determinants 
of Rho kinase inhibitors [23]. S6K1 and PKA share a 
sequence identity of approximately 33% in their kinase 
domains and their ATP-binding sites are nearly identical. 
Our PKA-S6K1 chimera was created by mutation of five 
residues in or near the ATP-binding site (F54Y, M120L, 
V123L, L173M and Q181K) that differ between the two 
kinases. Analogous to PKA and other PKA-based chimeric 
proteins, the PKA-S6K1 chimera could be expressed in 
E. coli and the tetra-phosphorylated enzyme purified 
using a protocol described previously (see Materials and 
Methods). Co-crystals of purified PKA-S6K1 chimera 
with PKA inhibitor peptide (PKI, residues 5-24) were 
successfully grown, routinely diffracted to between 1.5 and 
2.0 Å resolution, and ternary complexes with inhibitors 
could easily be obtained using soaking experiments. 
To validate the PKA-S6K1 chimera as a 
structural surrogate for S6K1, we solved the structure 
of staurosporine bound to the PKA-S6K1 chimera and 
compared it with the publicly available staurosporine-
bound crystal structures of PKA (PDB code: 1STC) and 
the phosphorylated and partially activated S6K1 (PDB 
code: 3A62). As expected, the overall conformations of 
the staurosporine-bound PKA and PKA-S6K1 structures 
are nearly identical (rmsd 0.51 Å for 330 equivalent Cα 
atoms, Figure 1), except for residues 316 to 320 in the 
C-terminal tail, which adopt a different conformation in 
the PKA-S6K1 chimera compared to PKA (Figure 1A). 
In both structures, the PDK1 phosphorylation site in the 
activation loop (Thr197) is in its phosphorylated state, the 
activation loop is in an optimal conformation for substrate 
binding and both structures are ternary complexes with 
the peptide inhibitor PKI. However, it is important to 
note that the binding of staurosporine induces substantial 
conformational changes in the structure of PKA [24] and 
therefore also in the structure of the PKA-S6K1 chimera. 
During its catalytic cycle, the conformation of the PKA 
kinase domain shuttles between an open unliganded 
conformation, and a closed ATP- and substrate-bound 
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conformation, which together with several intermediate 
conformations, have been captured in different PKA 
crystal structures [25]. Both the staurosporine-bound 
PKA and PKA-S6K1 structures are most similar to an 
intermediate conformation represented by the adenosine-
bound PKA structure (PDB code: 1BKX), in which the 
P-loop adopts a conformation halfway between the fully 
open and closed forms of the kinase (Figure 1C). In both 
staurosporine-bound crystal structures, changes in the side 
chain conformations of residues lining the respective ATP-
binding sites help to accommodate the binding of the bulky 
staurosporine molecule. The biggest differences include 
the conformation of the respective Phe54 or Tyr54 residue 
at the tip of the P-loop, which in both structures is tucked 
underneath the loop and points towards staurosporine, 
and the conformation of Phe327 in the C-terminal tail, 
whose side chain is not only shifted, but also rotated by 
approximately 90 degrees to allow binding of the inhibitor 
(Figure 1C).
The construct used to elucidate the native S6K1 
structure lacks 75 N-terminal residues and 126 C-terminal 
residues of the S6K1 sequence. In addition, the S6K1 
crystallographic coordinates lack a further 10 N-terminal 
residues and 27 C-terminal residues due to disorder 
of these residues within the crystals used for structure 
elucidation. Therefore, the native S6K1 crystal structures 
do not contain the C-terminal auto-inhibitory domain and 
the majority of the characteristic AGC kinase C-terminal 
tail [26], which folds back from the C-terminal lobe 
across the ATP-binding site to the N-terminal lobe, is not 
Figure 1: PKA, the PKA-S6K1 chimera and native S6K1. A) Superposition of the staurosporine-bound structures of PKA (PDB 
code: 1STC) in light green and the PKA-S6K1 chimera in light blue showing the close similarity of the structures. The inhibitor peptide 
PKI is shown in yellow and blue in the respective structures. The staurosporine molecules are shown in cylinder representation. Relevant 
secondary structure elements are labelled. B) Superposition of the staurosporine-bound structures of the PKA-S6K1 chimera in light blue 
and native S6K1 (PDB code: 3A62) in orange showing the similarity in their tertiary structures and the nearly identical binding mode of 
staurosporine. The inhibitor peptide PKI present in the PKA-S6K1 chimera structure is shown in blue. C) Close-up of the superposition of 
the staurosporine bound PKA-S6K1 chimera and the adenosine-bound PKA structure (PDB code: 1BKX) which represents an intermediate 
conformation in the PKA catalytic cycle. The colour scheme is the same as in panel A, but the adenosine molecule bound in 1BKX is 
not displayed for clarity. Phe327 in the C-terminal tail and the aromatic residue at the tip of the P-loop (Tyr54/Phe54) adopt different 
conformations in the respective structures. D) Close-up of the S6K1 and PKA-S6K1 chimera superposition. The positions of four of the five 
mutations in the PKA-S6K1 chimera ATP-binding site (Tyr54, Leu120, Leu123, Met173) are highlighted using the PKA-S6K1 sequence 
numbering. The fifth mutation near the ATP-binding site (Lys181) could not be shown in this orientation. Also shown is Tyr102 in S6K1. 
All structural figures were made using CCP4MG [48].
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present. Although the S6K1 construct is considerably 
shorter than the PKA and PKA-S6K1 chimera sequences, 
the overall tertiary SK61 structure is very similar to the 
PKA-S6K1 chimera (rmsd 1.33 Å for 247 equivalent Cα 
atoms, Figure 1B). The most notable differences with the 
PKA-S6K1 chimera include the disordered αB-helix and 
partially disordered activation loop and αC-helix, which 
are consistent with the low activity of the phospho-Thr252 
form of the enzyme. The binding-mode of staurosporine 
to native S6K1 and the PKA-S6K1 chimera is nearly 
identical, and the amino acid residues lining the respective 
ATP-binding sites and contacting staurosporine have very 
similar side chain conformations. The exception is the 
conformation of the tyrosine residue (Tyr102 in S6K1 
and Tyr54 in PKA-S6K1) at the tip of the P-loop, which 
extends outward in S6K1, but is folded back underneath 
the P-loop in the PKA-S6K1 chimera (Figure 1D). This 
could potentially be a cause of differences in inhibitor-
binding between native S6K1 and the PKA-S6K1 chimera, 
but because of the high similarity of the overall kinase 
domain structures and the very minor differences in side 
chain conformations within the respective staurosporine-
occupied ATP-binding sites, we concluded that the PKA-
S6K1 chimera was a suitable, robust and high-resolution 
surrogate system to guide our structure-based S6K 
inhibitor design.
High-throughput screening of S6K1.
To identify inhibitors of S6K1, an HTS using 
an AlphaScreen™ kinase assay was carried out which 
measured the inhibition of the catalytic domain of S6K1 
by the reduction in phosphorylation of an RPS6 substrate 
peptide. A compound library of approximately 67,000 
compounds with lead-like properties was screened at a 
final concentration of 30 μM. With a mean Z’ factor of 
0.69 ± 0.07 (CV% = 9.3) the overall performance of the 
HTS was considered to be good (Figure 2). A total of 414 
hits were identified yielding an initial hit rate of 0.6%. To 
exclude compounds active through aggregation, all initial 
hits were reanalysed using the same assay conditions in 
the presence of Triton™ X100 [27]. The 67 resulting hits 
(confirmed hit rate 0.1%) were inspected for chemical 
tractability, toxicophores and undesired compounds, which 
left 19 progressible hits of which 12 were commercially 
available and repurchased for further analysis. The IC50 
values of 11 of the 12 hits ranged from 0.25 to 22.6 
μM, but the remaining compound did not reconfirm in 
a secondary DELFIA phosphorylation assay and was 
therefore discarded. 
Hit evaluation.
The resulting confirmed HTS hits could be grouped 
into three chemical series and three singletons. The three 
chemical series were prioritised for investigation. 
The first series comprised three 
carboxamidobenzimidazoles (1 – 3) with respective IC50 
values of 0.56 μM, 1.04 μM and 10.14 μM (Figure 3 and 
Table 1). Their favourable physicochemical properties, 
including molecular weights ≤ 283 Da, ClogP ≤ 2.1, total 
polar surface areas (tPSA) ≤ 97 Å2, and their good ligand 
efficiencies made them an attractive series for further 
investigation. 
The carboxamidobenzimidazoles are known 
inhibitors of poly(ADP-ribose) polymerase (PARP) with 
activities in the low nanomolar range [28] and therefore 
our first aim was to attempt to divorce their S6K1 and 
PARP activities. It is known that the 4-carboxamide 
and its intramolecular hydrogen bond to the N-3 of the 
benzimidazole are crucial for PARP activity as this mimics 
the natural cofactor nicotinamide adenine dinucleotide 
(NAD+). Replacement of the amide by a carboxylic acid 
group gave compound 4, which is known to be inactive 
against PARP but also led to loss of activity against S6K1. 
Similarly, the N-methyl amide 5 was inactive against 
S6K1, as was the regioisomeric 5-carboxamide 6, which is 
another carboxamidobenzimidazole lacking PARP activity 
[28]. Initial docking studies and subsequent determination 
of the crystal structure of compound 1 bound to the PKA-
S6K1 chimera showed that the 4-carboxamide group is 
involved in crucial hydrogen interactions with the hinge 
region (Figure 4A), which explains the loss of potency 
upon modifications in this area of the molecule. The 
phenol group of 1 extends past the medium-sized Leu120 
Figure 2: Overall performance of the S6K1 high-
throughput screen. Alphascreen™ counts (mean ± SD) for 
total activity wells (■); no enzyme blanks (▼) and Z’ factor (●) 
for 16 batches of 14 plates containing 320 compounds each.
N
H
N
CONH2
R1
R2
N
H
N
OH
R3
R4
1 - 3 4 - 6
Figure 3: Carboxamidobenzimidazole hits
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gatekeeper into the selectivity pocket and interacts with 
the conserved Glu91 in the αC-helix. A superposition of 
the compound 1-bound PKA-S6K1 chimera structure 
with the S6K1 structure shows that 1 would fit in the 
ATP-binding site (Figure 4B). However, because the key 
features of these 2-arylbenzimidazole-4-carboxamides 
that lead to potent inhibition of S6K1 are also crucial 
to inhibition of PARP, we did not pursue this series any 
further. 
The second hit series consisted of three 
2,3-diaryl(3H)-quinazolin-4-ones (Figure 5). Although 
the compounds in this series had slightly higher ClogP 
values (2.8–4.0) than the benzimidazoles from series 1, 
the potencies and ligand efficiencies (Table 2) were still 
attractive. However, upon resynthesis of these compounds, 
it became clear that their physicochemical properties 
are far from ideal. Obtaining reliable assay results was 
difficult owing to limited aqueous solubility, and despite 
developing a new synthetic route to this series [29], it 
proved impossible to develop any directional structure-
activity relationships (SAR), which led us to discard this 
series.
The third hit series consisted of the two 
N-alkylbenzimidazoles compound 10 and compound 11 
which both have an amino-oxadiazole substituent at the 
C-2 position (Figure 6). Their respective IC50 values of 
340 nM and 7.0 μM translate to good ligand efficiencies 
(Table 3). At the start of our programme, compounds 
containing this ring system had been reported as inhibitors 
of the AGC kinases mitogen and stress-activated protein 
kinase (MSK1), Rho kinase (ROCK1), and AKT [30-
Table 1: IC50 values and ligand efficiencies of carboxamidobenzimidazole hits 1 – 3.
 
Compound R1 R2 R3 R4  S6K1 IC50 (μM)a LEc
1 OH H - - 0.56 ± 0.05 0.45
2 H OH - - 1.04 ± 0.16 0.44
3 OH OMe - - 10.1 ± 2.9 0.33
4 - - CO2H H >100b n/a
5 - - CONHMe H >100b n/a
6 - - H CONH2 >100b n/a
aThe IC50 values were taken from the confirmation DELFIA assays on repurchased samples and are expressed as the mean ± 
standard error for duplicate measurements. bSingle measurement. cLigand efficiencies were calculated using the mean IC50 
values [49]. 
Figure 4: The binding mode of compound 1. A) Crystal 
structure of the PKA-S6K1 chimera in complex with compound 
1. The compound is shown in cylinder representation with 
orange carbon atoms. PKA-S6K1 amino acids interacting with 1 
are displayed in cylinder representation with blue carbon atoms. 
Solvent atoms are displayed as red spheres and hydrogen bonds 
are shown as black dashed lines. The electron density shown as a 
blue mesh is a Fo-Fc omit map contoured at 3σ. B) Superposition 
of the structure of 1 bound to PKA-S6K1 with the S6K1 structure 
(PDB code: 3A62) showing that 1 fits in the S6K1 ATP-binding 
site. Compound 1 is shown in cylinder representation with blue 
carbon atoms. The S6K1 solvent accessible surface is shown in 
orange.
Figure 5: Diarylquinazolinone hits
N
N N
N
O Br
N
N
N
O
N
N
N
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N
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N
H2N
Figure 6: Benzimidazole oxadiazole hits
Table 2: IC50 values and ligand efficiencies 
of diarylquinazoline hits. 
Compound S6K1 IC50 (μM)a LEb
7 0.26 ± 0.15 0.38
8 1.55 ± 0.92 0.33
9 2.97 ± 1.53 0.33
aThe IC
50
 values were taken from the confirmation 
DELFIA assays on repurchased samples and are 
expressed as the mean ± standard error for duplicate 
measurements. bLigand efficiencies were calculated 
using the mean IC
50
 values [49]. 
Oncotarget 2013; 4:1652www.impactjournals.com/oncotarget
32], and the excellent properties of these hits (ClogP = 
2.8, tPSA = 76 Å2, Mw = 241/243 Da), led us to select 
the benzimidazole oxadiazole scaffold as a starting point 
for our SAR studies. During the course of our work our 
findings were reinforced by Bandarage et al. [33], who 
also reported benzimidazole oxadiazoles as attractive 
S6K1 inhibitors.
Exploration of the benzimidazole N-1 position.
It was initially decided to investigate simple alkyl 
modifications at the N-1 position of the benzimidazole 
scaffold. Several analogues were prepared according to 
well-established literature methods (Scheme 1) [33].
In agreement with the results of Bandarage et al., 
compounds 15b, 15c and 15e with the respective ethyl, 
cyclopropyl and cyclopropylmethyl substituents were 
most potent, but the N-methyl analogue compound 15a 
was about six-fold less active (Table 4). In addition, 
incorporation of the larger benzyl substituent (15d) 
resulted in complete loss of biochemical activity. The 
crystal structure of the PKA-S6K1 chimera bound to 
15e (Figure 7a) shows that its cyclopropylmethyl group 
fits snugly in a hydrophobic pocket formed by Gly50, 
Tyr54, Val57, and Phe327, as proposed by Banderage 
et al. [33], and suggests that this pocket is too small to 
accommodate the benzyl group of 15d. Superposition of 
15e on the staurosporine-bound S6K1 structure shows that 
the compound also fits in the native S6K1 ATP binding 
site, but owing to the disorder in the S6K1 C-terminal tail 
and the different conformation of the P-loop, the presence 
of the hydrophobic pocket binding the cyclopropyl group 
could not be verified (Figure 7b). 
Figure 7: Binding mode of compound 15e. A) Crystal 
structure of the PKA-S6K1 chimera in complex with compound 
15e. The compound is shown in cylinder representation with 
orange carbon atoms. PKA-S6K1 amino acids interacting 
with 15e are displayed in cylinder representation with blue 
carbon atoms. Hydrogen bonds are shown as black dashed 
lines. The electron density shown as a blue mesh is a Fo-Fc 
omit map contoured at 3σ. B) Superposition of the structure of 
15e bound to PKA-S6K1 with the S6K1 structure (PDB code: 
3A62) showing that 15e fits well in the S6K1 ATP-binding site. 
However, due to the flexibility in the S6K1 P-loop and disorder 
in the C-terminal tail it cannot be confirmed if the hydrophobic 
pocket binding the cyclopropyl group of 15e in the PKA-S6K1 
chimera is present in native S6K1. Compound 15e is shown 
in cylinder representation with blue carbon atoms. The S6K1 
solvent accessible surface is shown in orange.
NO2
F
NH2
NHR
N
N CN
N
N
N O
N
RR
H2N
a
b
c
12 13
1415
Scheme 1: Preparation of 2-aminooxadiazole 
benzimidazole derivatives. Reagents and conditions: (a) 
i. RNH2, KF, K2CO3, 50-100 ºC, ii. Pd(10%)/C, EtOH, rt or 
SnCl2·2H2O, reflux (77-86%, 2 steps); (b) ethyl cyanoacetate, 
195 ºC, 2 h (43-70%); (c) NaNO2, 6 M aq. HCl, MeOH then 6 M 
aq. NaOH, 50% aq. NH2OH, reflux (10-45%).
Table 3: IC50 values and ligand efficiencies 
of benzimidazole oxadiazole hits. 
Compound S6K1 IC50 (μM)a LEb
10 0.34 ± 0.14 0.50
11 6.98 ± 2.07 0.40
aThe IC50 values were taken from the confirmation DELFIA 
assays on repurchased samples and are expressed as the mean ± 
standard error for duplicate measurements. bLigand efficiencies 
were calculated using the mean IC50 values. 
Table 4: IC50 values and ligand efficiencies 
for N-1 substituted compounds 15 (Scheme 
1). 
Compound R S6K1 IC50 (nM)a LEe
15a Methyl 194d 0.58
15b Ethyl 59.8 ± 32.4b 0.59
15c Cyclopropyl 36.6 ± 7.0b 0.57
15d Benzyl >100000c n/a
15e Cyclopropylmethyl 19.8
d 0.56
aThe IC50 values were determined with a mobility shift assay. 
bMean ± standard deviation from triplicate measurements. 
cDuplicate measurement. dSingle measurement. eLigand 
efficiencies were calculated using the mean IC50 values.
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Acetylation on the exocyclic amino group of the 
aminooxadiazole moiety renders this series inactive 
against S6K, as shown by compound 16, with an IC50 value 
of greater than 100 μM (Scheme 2). This is consistent with 
the binding mode observed in the 15e-bound PKA-S6K1 
structure, in which the oxadiazole group binds to the hinge 
by the formation of a hydrogen bond between its N-2 atom 
and the backbone amide group of Leu123 and through a 
hydrogen bond between the exocyclic amino group with 
the backbone carbonyl of Glu121. Although the closely 
related acetylated compound 16 could in principle still 
form these hydrogen bonds, in this binding mode the 
acetyl group would clash with the gatekeeper residue 
Leu120 and Val104, situated at the bottom of the ATP-
binding site. 
Exploration of the benzimidazole C-5 and C-7 
positions.
Modifications on the benzene ring at the C-5 and 
C-7 positions were investigated as shown in Scheme 
3. Preparation of the requisite bromo-precursors 20a 
and 20f (Scheme 3) allowed the synthesis of analogues 
incorporating phenyl (20b), cyclopropyl (20c), methoxy 
(20d) and methylamino (20e) on the R1 position and 
3-pyridyl on the R2 position (20f, Scheme 3). However, 
unfortunately none of these modifications yielded an 
improvement in potency (Table 5). 
Azabenzimidazoles.
In order to diversify this scaffold, we chose to 
replace the benzimidazole ring with an azabenzimidazole. 
Azabenzimidazole aminooxadiazoles have been reported 
as potent Rho kinase inhibitors and upon analysis of their 
selectivity profile were also found to have a strong affinity 
for S6K [34]. Therefore we synthesised a limited set of 
azabenzimidazole analogues from the bromo-precursor 
21a using the synthetic route reported (see Scheme 4) 
[34]. Interestingly, 21a (Table 6) was equipotent with the 
N-1 cyclopropyl-substituted benzimidazole oxadiazole 
15c. Introduction of a phenoxy group in the C-6 position 
(21b) conferred some activity as already suggested by 
Scheme 3: Preparation of C-5 and C-7 substituted 
benzimidazoles; Reagents and conditions: (a) EtNH2, 
THF (quant.); (b) Na2S2O4, EtOH, reflux (90%); (c) i. CDI, 
cyanoacetic acid, THF, reflux; ii. acetic acid (81%, 2 steps); 
(d) NaNO2, 6 M aq. HCl, MeOH then 6 M aq. NaOH, 50% aq. 
NH2OH, reflux (54%); (e) i. n-Buli, B(OMe)3, THF then aq. H2O2 
(41%); ii. MeI, K2CO3, acetone (80%); (f) i. trifluoroacetamide, 
CuI, N,N’-dimethylethylenediamine, K2CO3, dioxane (25%); ii. 
MeI, KOH, acetone, reflux then 5% aq. NaOH, EtOH, reflux 
(70%); (g) PhB(OH)2 or cyclopropylboronate ester or 3-pyridine 
boronic acid, Pd(PPh3)4, 1 M aq. NaOH, DME, 150 ºC (71%,15% 
and 25% respectively). 
R1
R2
NO2
F
R1
R2
NH2
N
H
a,b
c
17 18
N
NR1
R2
CN
19
N
NR1
R2
N O
N
H2N
20
d,e,f or g
Table 5: IC50 values and ligand efficiencies 
of C-5 and C-7 substituted benzimidazoles 
(Scheme 3). 
Compound R1 R2
S6K1 
IC50 (nM) a
LEc
20a  Br H 66.4 ± 5.6 0.55
20b Ph H 1640 ± 530 0.35
20c cyclopropyl H 334 ± 25.1 0.45
20d OMe H 63.4b 0.52
20e NHMe H 148b 0.50
20f  H Br 303 ± 21 0.50
20g H
N
352 ± 173 0.39
aThe IC
50
 values were determined with a mobility shift 
assay and expressed as the mean ± standard deviation 
for triplicate measurements. bSingle measurement. 
cLigand efficiencies were calculated using the mean 
IC
50
 values.
Scheme 2: Preparation of 2-acetamide-oxadiazole 
derivative 16. Reagents and conditions: AcCl, rt (70%).
N
N
N O
N
H2N
N
N
N O
N
HN
O
15c 16
IC50 >100 µM
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the selectivity studies on Rho kinase. Substitution with a 
phenyl group at C-6 (21c) turned out to be detrimental 
and abolished all affinity for S6K1. An attempt to improve 
the physicochemical properties by introducing amino-side 
chains such as a morpholine group α-to the N-atom (21d) 
also proved unsuccessful. However, the methyl-substituted 
compound 21e represented the most potent inhibitor 
within this series, and with its ligand efficiency of 0.6 
could prove to be an attractive tool compound for further 
S6K studies (Table 6).
The binding mode of both the synthetic precursor 
21a and 21e was determined by solving the crystal 
structures of these inhibitors in complex with the PKA-
S6K1 chimera (Figure 8). Both compounds bind to 
PKA-S6K1 in the same orientation as the benzimidazole 
oxadiazoles with the azabenzimidazole nitrogen forming 
an additional hydrogen bond interaction with the catalytic 
Lys72, which in turn forms the conserved salt bridge 
with Glu91 located in the αC-helix. In both structures the 
respective bromo and methyl C-6 substituents pack against 
the side chain ring of Tyr54, located at the tip of the 
P-loop and are found to be involved in protein-inhibitor 
interactions in other kinases such as PKB [21].
Comparison of the binding modes of identified 
S6K1 inhibitors.
The PKA-S6K1 inhibitor structures described in 
this paper are most similar to the intermediate adenosine-
bound PKA conformation (PDB code: 1BKX). In all 
structures, Phe327 adopts a conformation similar to the 
one observed in PKA and consistent with shielding the 
bound ligand from the solvent.  
The carboxamidobenzimidazole 1 is the only 
inhibitor which binds in the selectivity pocket, whereas 
the benzimidazole-oxadiazole 15e and azabenzimidazole-
oxadiazoles 21a and 21e bind in a very similar manner 
exploiting the small hydrophobic pocket formed by 
Phe327 from the C-terminal tail, Gly50 and Tyr54 from the 
P-loop (Figure 9A). Interestingly, in the benzimidazole and 
azabenzimidazole inhibitors the aromatic Tyr54 at the tip 
of the P-loop closes in over the inhibitor and packs against 
the hydrophobic side of the inhibitors. In compounds 21a 
and 21e, Tyr 54 interacts with the respective bromine 
and methyl groups, but the effect is most pronounced for 
compound 15e, which is unsubstituted in this position 
allowing Tyr54 to interact directly with the core scaffold 
of the inhibitor (Figure 9B). The closing of the P-loop over 
these inhibitors effectively shields them from the solvent, 
which together with the hydrophobic stacking interactions 
is likely to contribute to the potency of these inhibitors.  
N
N
N
Br N O
N
H2N
N
N
N
R N O
N
H2N
N
N
N
O N O
N
H2N
N
N
N
N N O
N
H2N
S OOO
a
b
21a
21b
21c,e
21d
c
Scheme 4: Preparation of azabenzimidazole 
derivatives. Reagents and conditions: (a) RB(OH)2, Pd(PPh3)4, 
1 M aq. NaOH, DME, 150 ºC  microwave [R = Me (25%),  R 
= Ph (59%)]; (b) methyl-(3-hydroxyphenyl)sulfone, Cs2CO3, 
Cu (10 mol%), Fe(acac)3 (30 mol%), DMF, 150 ºC, microwave 
(17%); (c) morpholine, NMP, 160 ºC  microwave (51%).
Table 6: IC50 values and ligand efficiencies 
of azabenzimidazoles (Scheme 4). 
Compound R S6K1 IC50 (nM) a LEd
21a Br 19.7 ± 2.6 0.59
21b OS
OO
103 ± 23b 0.34
21c Ph >100000 n/a
21d morpholine 110c 0.42
21e Me 17.4 ± 6.0 0.60
aThe IC50 values were determined with a mobility shift assay 
and expressed as the mean ± standard deviation for triplicate 
measurements. bMean value from duplicate measurement ± 
standard error. cSingle measurement. dLigand efficiencies were 
calculated using the mean IC50 values.
Figure 8: The binding mode of azabenzimidazoles 21a 
and 21e. A) Crystal structure of the PKA-S6K1 chimera in 
complex with the synthetic precursor compound 21a. B) Crystal 
structure of the PKA-S6K1 chimera in complex with compound 
21e. The compounds are shown in cylinder representation 
with orange carbon atoms. PKA-S6K1 amino acids interacting 
with the respective compounds are displayed in cylinder 
representation with blue carbon atoms. Hydrogen bonds are 
shown as black dashed lines. The electron density shown as a 
blue mesh are Fo-Fc omit maps contoured at 3σ. 
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Cellular activity of azabenzimidazole 21e 
(CCT239066).
We examined the activity of the substituted-
azabenzimidazole 21e (CCT239066) in a human bladder 
carcinoma line (HCV29) that has activated mTOR 
signalling as a result of losing expression of the TSC 
complex which allows activation of mTORC1 [35]. 
CCT239066 (21e) inhibits S6K1 with IC50 values of 
17.4 ± 6.0 nM and S6K2 at 300 ± 102 nM respectively 
and demonstrated 50% tumour growth inhibition 
(GI50) at a concentration of 3.5 μM following 96 hours 
continuous exposure. CCT239066 (21e) also inhibited 
phosphorylation of a biomarker of S6K1 activity, 
phosphorylation of RPS6 at Ser235/236 (Figure 10) in 
intact cells. The EC50 for 50% inhibition of Ser235/236 
phosphorylation following 2 hours exposure was 9.1 ± 
1.5 μM (n=3) compared to IC50 values > 15 μM for AKT-
Thr308, AKT-Ser473, GSK3b-Ser9 and S6K-Ser421/424 
as determined by electrochemoluminescent ELISA in 
intact cells.
In conclusion, we have identified three different 
chemical series of S6 kinase inhibitors. Optimisation of 
the benzimidazole oxadiazole series resulted in a potent, 
ligand efficient azabenzimidazole S6K1/S6K2 inhibitor 
with good physicochemical properties and cellular activity. 
In addition, we developed a novel robust crystallography 
system based on a PKA-S6K1 chimera and experimentally 
determined the binding mode of two of the three inhibitor 
series, including the improved and cellularly active 
azabenzimidazole inhibitor. The availability of both 
a robust crystallography system and cellularly active 
tool compounds will aid the future design of potent and 
selective S6K inhibitors. 
METHODS
High-throughput screening of S6K1.
The catalytic domain of S6K1 was screened against 
our in-house HTS library of lead-like compounds using 
an AlphaScreen™ kinase assay in which inhibition of 
S6K1 was measured by a reduction in the phosphorylation 
of a S6 peptide. Compounds were screened at a final 
concentration of 30 μM and 0.3% (v/v) DMSO by 
dispensing 3 μL compound solution from a source plate 
containing the compounds at a concentration of 200 
μM in 2% (v/v) DMSO, into the central 320 wells of a 
polypropylene 384-well assay plate (#781287; Greiner 
Bio-One, Frickenhausen, Germany). 0.3% (v/v) DMSO 
was used as a vehicle control. 17 μL of the reaction 
mixture containing 1 nM S6K1 (#14-486; Millipore, 
Billerica, MA, USA), 30 μM ATP and 250 nM S6 peptide 
(Biotin-KRRRLSSLRASTSKSESSQKI, synthesised by 
J. Metcalfe, ICR) in assay buffer consisting of 40 mM 
HEPES pH 7.5, 10 mM MgCl2, 1 mM DTT and 0.02% 
(v/v) Tween 20, was added to the compound plate and 
incubated for an hour at room temperature. Each 384 well 
plate contained 32 control wells for total enzyme activity, 
no enzyme blanks and the positive control, staurosporine 
at a final concentration of 20 nM. The reaction was 
stopped by the addition of 80 μL of 50 mM EDTA pH 
7.5. An aliquot containing 10 μL of the assay solution 
was transferred to a white OptiPlate™ (#6007299; 
PerkinElmer Life Sciences, Waltham, MA, USA). 
AlphaScreen™ streptavidin-coated donor beads, protein 
Figure 10: Inhibition of RPS6 phosphorylation. Results 
from an electrochemiluminscent ELISA assay showing the dose-
dependent inhibition of phosphorylation of RPS6 on serine 235 
and serine 236 in HCV29 human bladder cancer cells following 
a two hour exposure to compound 21e. 
Figure 9: Comparision of 4-carboxamidobenzimidazole 
and benzimidazole-oxadiazole with PKA. A). 
Superposition of the compound 1 bound PKAS6K1 structure 
(light-blue) with the intermediate adenosine-bound PKA 
structure (PDB code: 1BKX, lemon yellow). Compound 1 is 
shown in pink. The phenol group of compound 1 extends into the 
selectivity pocket. B) Superposition of the compound 15e bound 
PKA-S6K1 structure (light blue) with 1BKX (lemon yellow). 
Compound 15e is shown in pink. Tyr54 at the tip of the P-loop 
of the PKA-S6K1 chimera swings towards the benzimidazole 
core scaffold of the inhibitor. In both inhibitor-bound structures 
Phe327 is in a similar conformation as observed in the adenosine-
bound structure. 
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A-conjugated acceptor beads (#6760617M; PerkinElmer 
Life Sciences) and anti-phospho S6 antibody (#2211; Cell 
Signalling Technology Inc., Danvers, MA, USA) were 
diluted in bead buffer comprising 40 mM HEPES pH 7.5, 
40 mM NaCl, 5% (v/v) glycerol and 0.125% BSA and 
added to the OptiPlate™ resulting in a final concentration 
of 0.1 nM antibody and 10 μg/mL beads. Plates were 
sealed and incubated overnight at room temperature in the 
dark before being read on the Fusion™ Multilabel Reader 
(PerkinElmer Life Sciences). Using a 300 ms excitation 
at 680 nm and 700 ms per well reading time at 520-620 
nm the signal was expressed in counts per second. A 
MiniTrak™ V (PerkinElmer Life Sciences) was used for 
compound and reagent addition. Primary screening data 
were analysed in ActivityBase (IDBS, Guildford, UK). 
Compounds with a percentage inhibition of 50% or better 
were classed as initial hits. All hits were cherry-picked 
and re-assayed in triplicate to confirm activity. In addition, 
the hits were tested for aggregation by assaying them in 
triplicate with 0.01% (v/v) Triton™ X-100 added to the 
assay buffer.
General synthetic chemistry.
Reactions were carried out under nitrogen or argon 
when necessary. Organic solutions were dried over 
MgSO4. Starting materials and solvents were purchased 
from commercial suppliers and were used without further 
purification. Microwave reactions were carried out using 
a Biotage Initiator 60 microwave reactor. Flash silica 
chromatography was performed using Merck silica gel 
60 (0.025-0.04 mm) and ethylacetate/petroleum spirit 
(40-60). Ion exchange chromatography was performed 
using Isolute Flash SCX-II (acidic). 1H NMR spectra were 
recorded on a Bruker AMX500 instrument using internal 
deuterium lock. 13C NMR spectra were recorded at 125 
MHz on a Bruker AMX500 instrument. Chemical shifts 
(δ) are reported relative to TMS (δ=0) and/or referenced 
to the solvent in which they were measured. Combined 
HPLC-MS analyses were recorded using a Waters Alliance 
2795 separations module and Waters/Micromass LCT 
mass detector with electro spray ionization (+ve or -ve 
ion mode as indicated) and with HPLC performed using 
Supelco DISCOVERY C18, 50 mm x 4.6 mm or 30 mm 
x 4.6 mm i.d. columns, at a temperature of 22 °C with 
gradient elution of 10-90% MeOH/0.1% aqueous formic 
acid at a flow rate of 1 mL/min and a run time of 6 min. 
Compounds were detected at 254 nm using a Waters 2487 
dual λ absorbance detector. All tested compounds gave 
95% purity as determined by this method. All purified 
synthetic intermediates gave 95% purity as determined 
by this method except where indicated in the text. High-
resolution mass spectra were measured on an Agilent 6210 
ToF HPLC-MS with a Phenomenex Gemini 3 μm C18 (3 
cm x 4.6 mm i.d.) column.
The synthesis of the key oxadiazole-substituted 
benzimidazoles and azabenzimidazoles 15a-e, 16, and 
21b-e from their respective precursors is described 
below. For details of the synthesis of all precursors and 
compounds 20a-g see the supplementary information.
4-(1-Methyl-1H-benzoimidazol-2-yl)-1,2,5-
oxadiazole-3-ylamine (15a).
Benzimidazole 14a (342 mg, 2.00 mmol) was 
diluted in MeOH (2 mL) and aqueous HCl (6 M, 1.5 mL). 
Solid NaNO2 (166 mg, 2.40 mmol, 1.2 equiv.) was added 
portionwise over 10 min. After the addition, the reaction 
mixture was made basic with the addition of aqueous 
NaOH (6 M, 1.5 mL) and hydroxylamine (50% aqueous 
solution, 0.68 mL, 10.27 mmol, 5.1 equiv.) was added. 
The reaction mixture was heated to reflux for 4 h, cooled 
and filtered (H2O and MeOH). Purification of the resulting 
solid by chromatography (SiO2, petroleum spirit/EtOAc: 
70/30) afforded the title compound as a light yellow solid 
(254 mg, 45%). 1H NMR (500 MHz, DMSO-d6): δ=7.82 
(d, J=8.1 Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.44 (ddd, 
J=1.0, 7.1, 8.1 Hz, 1H), 7.35 (ddd, J=1.0, 7.1, 8.1 Hz, 
1H), 6.99 (br s, 2H), 4.16 ppm (s, 3H); 13C NMR (125 
MHz, DMSO-d6): δ=156.1 (s), 141.5 (s), 140.9 (s), 138.4 
(s), 135.8 (s), 124.4 (d), 123.0 (d), 119.8 (d), 111.1 (d), 
32.2 ppm (q); LC-MS: m/z: 216 [M+H]+, Rt = 4.39 min; 
HR LC-MS: m/z calcd for C10H10N5O: 216.0879 [M+H]+; 
found: 216.0878. 
4-(1-Ethyl-1H-benzoimidazol-2-yl)-1,2,5-
oxadiazole-3-ylamine (15b).
The benzimidazole 14b (574 mg, 3.10 mmol) was 
dissolved in MeOH (2.5 mL) and aqueous HCl (6 M, 
2.3 mL). Solid NaNO2 (256 mg, 3.72 mmol, 1.2 equiv.) 
was added portionwise over 10 min. After the addition, 
the reaction mixture was made basic with aqueous NaOH 
(6 M, 2.3 mL) and hydroxylamine hydrochloride (226 
mg, 3.25 mmol, 1.05 equiv.) was added. The reaction 
mixture was heated to reflux for 2 h, cooled and filtered 
(H2O and MeOH). Purification of the resulting solid by 
chromatography (SiO2, petroleum spirit/EtOAc: 70/30) 
afforded the title compound as a yellow solid (62 mg, 
9%). 1H NMR (500 MHz, DMSO-d6): δ=7.82 (d, J=7.8 
Hz, 1H), 7.79 (d, J=7.8 Hz, 1H), 7.43 (m, 1H), 7.36 (m, 
1H), 6.97 (br s, 2H), 4.70 (m, 2H), 1.39 ppm (t, J=6.3 Hz, 
3H); 13C NMR (125 MHz, DMSO-d6): δ=156.1 (s), 141.7 
(s), 140.1 (s), 138.1 (s), 134.7 (s), 124.5 (d), 123.1 (d), 
120.0 (d), 111.0 (d), 40.1 (t), 14.8 ppm (q); LC-MS: m/z: 
230 [M+H]+, Rt = 4.65 min; HR LC-MS: m/z calcd for 
C11H12N5O: 230.1036 [M+H]+; found: 230.1036.
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4-(1-Cyclopropyl-1H-benzoimidazol-2-yl)-1,2,5-
oxadiazole-3-ylamine (15c).
The benzimidazole 14c (318 mg, 1.61 mmol) was 
diluted in MeOH (1 mL) and aqueous HCl (6 M, 1.5 
mL). Solid NaNO2 (135 mg, 1.93 mmol, 1.2 equiv.) was 
added portionwise over 10 min. After the addition, the 
reaction mixture was made basic with aqueous NaOH (6 
M, 1.5 mL) and hydroxylamine (50% aqueous solution, 
0.55 mL, 8.30 mmol, 5.1 equiv.) was added. The reaction 
mixture was heated to reflux for 3 h, cooled and filtered 
(H2O and MeOH). Purification of the resulting solid by 
chromatography (SiO2, petroleum spirit/EtOAc: 70/30) 
afforded the title compound as a green solid (154 mg, 
40%). 1H NMR (500 MHz, DMSO-d6): δ=7.81 (d, J=8.1 
Hz, 1H), 7.76 (d, J=8.1 Hz, 1H), 7.43 (apparent td, J=1.0, 
8.1 Hz,1H), 7.35 (apparent td, J=1.0, 8.1 Hz, 1H), 6.91 (br 
s, 2H), 3.66 (m, 1H), 1.31-1.27 (m, 2H), 1.04-1.01 ppm 
(m, 2H); 13C NMR (125 MHz, DMSO-d6): δ=156.1 (s), 
142.3 (s), 141.4 (s), 138.1 (s), 135.9 (s), 124.4 (d), 123.1 
(d), 120.1 (d), 112.0 (d), 26.7 (d), 8.3 ppm (t); LC-MS: 
m/z: 242 [M+H]+, Rt = 4.67 min; HR LC-MS: m/z calcd 
for C12H12N5O: 242.1036 [M+H]+; found: 242.1038.
4-(1-Benzyl-1H-benzoimidazol-2-yl)-1,2,5-
oxadiazole-3-ylamine (15d).
The benzimidazole (14d) (249 mg, 1.00 mmol) 
was diluted in MeOH (3 mL) and aqueous HCl (6 M, 1 
mL). Solid NaNO2 (83 mg, 1.2 mmol, 1.2 equiv.) was 
added portionwise over 10 min. After the addition, the 
reaction mixture was made basic with aqueous NaOH 
(6 M, 1 mL) and hydroxylamine (50% aqueous solution, 
0.34 mL, 5.1 mmol, 5.10 equiv.) was added. The reaction 
mixture was heated to reflux for 5 h, cooled and filtered 
(H2O and MeOH). Purification of the resulting solid by 
chromatography (SiO2, petroleum spirit/EtOAc: 70/30) 
afforded the title compound as a white solid (124 mg, 
43%). 1H NMR (500 MHz, DMSO-d6): δ=7.87 (d, J=7.0 
Hz, 1H), 7.72 (d, J=7.0 Hz, 1H), 7.41 (ddd, J=1.2, 7.1, 8.3 
Hz, 1H), 7.37 (ddd, J=1.2, 7.1, 8.3 Hz, 1H), 7.30 (m, 2H), 
7.24 (m, 1H), 7.15 (m, 2H), 7.03 (br s, 2H), 5.97 ppm (s, 
2H); 13C NMR (125 MHz, DMSO-d6): δ=156.1 (s), 141.7 
(s), 140.6 (s), 138.1 (s), 136.4 (s), 135.3 (s), 128.7 (2d), 
127.5 (d), 126.5 (2d), 124.8 (d), 123.4 (d), 120.1 (d), 
111.5 (d), 48.0 ppm (t); LC-MS: m/z: 292 [M+H]+, Rt = 
5.07 min; HR LC-MS: m/z calcd for C16H14N5O: 292.1193 
[M+H]+; found: 292.1199.
4-(1-Cyclopropylmethyl-1H-benzoimidazol-2-yl)-
1,2,5-oxadiazole-3-ylamine (15e). 
NaH (30 mg, 0.765 mmol) was added to a stirred 
solution of 2-aminoxadiazole benzimidazole (0.140 g, 
0.696 mmol), in DMF (10 mL) at room temperature. 
The mixture was stirred at room temperature for 45 min, 
followed by the drop-wise addition of (bromomethyl)
cyclopropane (0.188 g, 1.392 mmol) dissolved in DMF 
(1 mL). This mixture was heated at 65 °C for 18 h. 
After cooling to room temperature, the excess DMF 
was removed under reduced pressure and the resulting 
mixture was diluted with diethyl ether (50 mL). The 
organic mixture was washed with water and brine before 
drying over MgSO4. The excess solvent was removed 
under reduced pressure and the residue purified by flash 
chromatography (SiO2; EtOAc:hexane; 1:4) to afford title 
compound 15e (86 mg, 46%) as a white solid. 1H NMR 
(500 MHz, DMSO-d6): δ=7.82 (m, 2H), 7.43 (m, 1H), 7.36 
(m, 1H), 6.99 (s, 2H), 4.59 (d, J=7.0 Hz, 2H), 1.36 (m, 
1H), 0.48 ppm (m, 4H); 13C NMR (125 MHz, DMSO-d6): 
δ=156.2, 141.7, 140.2, 138.2, 135.4, 124.6, 123.1, 119.9, 
111.5, 48.8, 11.3, 3.4 ppm; LC-MS: m/z: 256.11 [M+H]+, 
Rt = 2.90 min; HR LC-MS: m/z calcd for C13H13N5O: 
256.2752  [M+H]+; found: 256.1194.
N-[4-(1-Cyclopropyl-1H-benzoimidazol-2-yl)-
1,2,5-oxadiazole-3-yl]-acetamide (16). 
A mixture of amino-oxadiazole (15c) (50 mg, 0.207 
mmol) and acetyl chloride (0.5 mL, 7.03 mmol) was 
stirred at room temperature for 2 h. The reaction mixture 
was partitioned between EtOAc and saturated aqueous 
sodium bicarbonate solution (200 mL). After separation, 
the organic phase was washed with brine, dried over 
MgSO4 and evaporated under vacuum. The crude product 
was purified by flash chromatography (SiO2, petroleum 
spirit/EtOAc, gradient: 80/20 to 70/30) to give 41 mg 
(70%) of the title compound as a white solid. 1H NMR 
(500 MHz, CDCl3): δ=11.07 (s, 1H), 7.84 (d, J=8.1 Hz, 
1H), 7.72 (d, J=8.1 Hz, 1H), 7.60 (td, J=7.2, 1.0 Hz, 1H), 
7.42 (td, J=7.2, 1.0 Hz, 1H), 3.77–3.45 (m, 1H), 2.46 (s, 
3H), 1.45 (q, J=6.7 Hz, 2H), 1.20–1.04 ppm (m, 2H); 13C 
NMR (125 MHz, DMSO-d6): δ=168.3 (s), 150.1 (s), 141.6 
(s), 141.2 (s), 135.9 (s), 124.4 (d), 123.1 (d), 120.2 (d), 
111.9 (d), 99.5 (s), 26.0 (d), 23.3 (t), 7.7 ppm (t); LC-MS: 
m/z: 242 [M–(CH3C=O)+H]+, Rt = 2.41 min; HR LC-
MS:  m/z calcd for C14H14N5O2: 284.1142 [M+H]+; found: 
284.1143.
4-[1-Ethyl-6-(3-methanesulfonyl-phenoxy)-1H-
imidazo[4,5-c]pyridin-2-yl]-1,2,5-oxadiazole-3-
ylamine (21b).
A glass tube (evacuated and back-filled with Ar) was 
charged with Fe(acac)3 (16.5 mg, 0.047 mmol), Cu powder 
(1.0 mg, 0.016 mmol), methyl-(3-hydroxyphenyl)sulfone 
(40 mg, 0.23 mmol), and Cs2CO3 (102 mg, 0.31 mmol). 
Bromoazabenzimidazole 21a (50 mg, 0.156 mmol) was 
added under Ar followed by anhydrous DMF (1.5 mL). 
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The tube was sealed under Ar, and the mixture was heated 
to 150 ºC under microwave irradiation for 30 min. After 
cooling to room temperature, the mixture was diluted with 
dichloromethane and filtered. The filtrate was concentrated 
in vacuo and partitioned between water and EtOAc. After 
separation, the water phase was extracted with EtOAc and 
the organics were combined, washed twice with water, 
dried over MgSO4 and concentrated. Purification of the 
residue by flash chromatography on silica gel (EtOAc/
petroleum spirit, gradient: 40/60 to 70/30) afforded 21b 
(12 mg, 25%) as a white solid (13 mg, 20%). 1H NMR 
(500 MHz, DMSO-d6): δ=8.79 (s, 1H), 7.75 (apparent dt, 
J=1.2, 7.9 Hz, 1H), 7.70 (apparent t, J=7.9 Hz, 1H), 7.67 
(s, 1H), 7.63 (apparent t, J=2.0 Hz, 1H), 7.50 (ddd, J=1.0, 
2.3, 8.0 Hz, 1H), 6.92 (s, 2H), 4.70 (q, J=7.1 Hz, 2H), 3.25 
(s, 3H), 1.41 ppm (t, J=7.1 Hz, 3H); 13C NMR (125 MHz, 
DMSO-d6): δ=158.2 (s), 156.1 (s), 155.6 (s), 143.1 (s), 
143.0 (s), 142.2 (s), 140.0 (d), 137.8 (s), 137.1 (s), 130.9 
(d), 125.3 (d), 122.1 (d), 118.2 (d), 93.7 (d), 43.3 (q), 40.6 
(t), 14.6 ppm (q); LC-MS: m/z: 401 [M+H]+, Rt = 2.27 
min; HR LC-MS: m/z calcd for C17H17N6O4S: 401.1026 
[M+H]+; found: 401.1026.
4-(1-Ethyl-6-phenyl-1H-imidazo[4,5-c]pyridin-2-
yl)-1,2,5-oxadiazole-3-ylamine (21c).
PhB(OH)2 (30 mg, 0.24 mmol), 1 M aqueous NaOH 
(0.48 mL, 0.48 mmol) and Pd(PPh3)4 (9.3 mg, 0.008 
mmol) were added to a solution of 21a (50 mg, 0.16 mmol) 
in dimethoxyethane (DME, 2 mL). The reaction mixture 
was heated in a microwave reactor at 140 ºC for 1.5 h. The 
reaction mixture was then partitioned between saturated 
aqueous NH4Cl solution and EtOAc. After separation, 
the organic phase was washed with brine, dried over 
MgSO4 and evaporated under vacuum. The residue was 
first purified by ion exchange chromatography on SCX-II 
acidic resin (2 g) eluting with MeOH then a 2 M solution 
of NH3 in MeOH. After concentration, the resulting solid 
was purified on a small pad of silica gel (EtOAc/petroleum 
spirit, gradient: 30/70 to 50/50) to afford 21c (29 mg, 59%) 
as a white solid. 1H NMR (500 MHz, DMSO-d6): δ=9.20 
(s, 1H), 8.46 (s, 1H), 8.25 (d, J=7.3 Hz, 2H), 7.53 (dd, app 
t, J=7.7 Hz, 2H), 7.44 (dd, app t, J=7.3 Hz, 1H), 6.96 (s, 
2H), 4.79 (q, J=7.1 Hz, 2H), 1.45 ppm (t, J=7.1 Hz, 3H); 
13C NMR (125 MHz, DMSO-d6): δ=156.2 (s), 150.5 (s), 
142.4 (s), 142.3 (d), 140.8 (s), 139.1 (s), 138.5 (s), 137.9 
(s), 128.8 (d), 128.6 (d), 128.5 (d), 126.8 (d), 102.4 (d), 
40.5 (t), 14.9 ppm (q); LC-MS: m/z: 307 [M+H]+, Rt = 
2.23 min; HR LC-MS:  m/z calcd for C16H15N6O: 308.1329 
[M+H]+; found: 308.1337.
4-(1-Ethyl-6-morpholin-4-yl-1H-imidazo[4,5-c]
pyridin-2-yl)-1,2,5-oxadiazole-3-ylamine (21d).
Morpholine (0.07 mL, 0.81 mmol) was 
added to a solution of 21a (25 mg, 0.081 mmol) in 
N-methylpyrrolidinone (0.5 mL). The reaction mixture 
was heated in a microwave reactor at 160 ºC for 3 h. The 
mixture was cooled and concentrated. Purification of the 
crude by preparative TLC, eluting with EtOAc afforded 
21d (13 mg, 51%) as a yellow solid. 1H NMR (500 MHz, 
DMSO-d6): δ=8.73 (s, 1H), 7.04 (s, 1H), 6.90 (s, 2H), 
4.61 (q, J=7.1 Hz, 2H), 3.87-3.67 (m, 4H), 3.61-3.42 (m, 
4H), 1.36 ppm (t, J=7.1 Hz, 3H); 13C NMR (125 MHz, 
DMSO-d6): δ=156.7 (s), 156.0 (s), 142.5 (s), 140.6 (s), 
140.3 (d), 137.9 (s), 133.7 (s), 86.1 (d), 66.0 (t), 46.2 (t), 
40.0 (t), 14.6 ppm (q); LC-MS: m/z: 316 [M+H]+, Rt = 
2.50 min; HR LC-MS: m/z calcd for C14H18N7O2: 316.1516 
[M+H]+; found: 316.1515.
4-(1-Ethyl-6-methyl-1H-imidazo[4,5-c]pyridin-2-
yl)-1,2,5-oxadiazole-3-ylamine (21e).
MeB(OH)2 (29 mg, 0.48 mmol), 1 M aqueous 
NaOH (0.65 mL, 0.65 mmol) and Pd(PPh3)4 (9.3 mg, 
0.008 mmol) were added to a solution of 21a (50 mg, 0.16 
mmol) in DME (2 mL). The reaction mixture was heated 
in a microwave reactor at 140 ºC for 2 h. The reaction 
mixture was then partitioned between saturated aqueous 
NH4Cl solution and EtOAc. After separation, the organic 
phase was washed with brine, dried over MgSO4 and 
evaporated under vacuum. Purification of the residue by 
flash chromatography (SiO2, EtOAc) afforded 21e (12 mg, 
25%) as a white solid. 1H NMR (500 MHz, DMSO-d6): 
δ=8.99 (s, 1H), 7.70 (s, 1H), 6.93 (s, 2H), 4.66 (q, J=7.2 
Hz, 2H), 2.63 (s, 3H), 1.39 ppm (t, J=7.2 Hz, 3H); 13C 
NMR (125 MHz, DMSO-d6): δ=156.1 (s), 151.7 (s), 141.8 
(d), 141.5 (s), 140.2 (s), 137.9 (s), 137.3 (s), 104.5 (d), 
40.3 (t), 24.3 (t), 14.7 ppm (q); LC-MS: m/z: 245 [M+H]+, 
Rt = 1.73 min; HR LC-MS: m/z calcd for C11H13N6O: 
245.1145 [M+H]+; found: 245.1151.
Crystallisation and structure determination.
Crystallisation of the PKA-S6K1 chimera was 
performed using the same conditions as previously 
reported for the PKA/PKB chimera [21]. Prior to 
crystallisation, the purified protein was concentrated to 
18 mg/mL in crystallisation buffer consisting of 25 mM 
MES-Bis/Tris pH 6.5, 75 mM LiCl, 0.1 mM EDTA, 1 
mM octanoyl-N-methylglucamide and 1 mM DTT and 
containing 1 mM PKA-inhibitor peptide PKI (residues 
5-24, Sigma-Aldrich) or an in-house synthesised 
peptide corresponding to residues 5-22 of the PKA-
inhibitor peptide, but terminating with an amide at the 
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C-terminus. Crystals of the PKA-S6K1/PKI staurosporine 
ternary complex were obtained by streak-seeding into 
fresh hanging drops containing the same protein and 
reservoir solutions as used for the crystallisation of the 
binary PKA-S6K1/PKI complex, with the addition 
of 0.5 mM staurosporine. All other protein-inhibitor 
complexes were obtained by soaking experiments of 
selected inhibitors at a final concentration of 1 mM as 
previously described for PKA [21]. Crystals were briefly 
transferred to a cryoprotectant solution containing 22.5% 
(v/v) 2-methyl-2,4-pentanediol, 25 mM MES-Bis/Tris 
pH 6.5, 0.1 mM EDTA and 1 mM DTT, prior to flash-
cooling in liquid nitrogen. The data for the binary PKA-
S6K1/PKI complex were collected at beamline ID14EH2 
at the ESRF (Grenoble, France). Data for the ternary 
PKA-S6K1/PKI/inhibitor complexes were collected at 
the following beamlines: staurosporine- and compound 
1-bound complexes were collected at beamline I02 of the 
Diamond Light Source (Oxfordshire, UK) and the data for 
the protein-inhibitor complexes with compounds 15e, 21a, 
and 21e were collected at beamline ID14EH4 at the ESRF. 
All data sets were integrated, merged and scaled using the 
programs iMosflm [36], Pointless and Aimless [37, 38] 
from the CCP4 suite [39] (see Supplementary Table S1 for 
data collection and refinement statistics). The PKA-S6K1/
PKI structure was solved by molecular replacement using 
PHASER [40] with a PKA structure (PDB code: 2GFC) 
as a search model, after removal of all water molecules 
and truncation of the 5 mutated amino acids to alanine. 
All protein-inhibitor structures were solved by molecular 
replacement with the PKA-S6K1/PKI structure as a search 
model after removal of all water molecules. All structures 
were manually rebuilt in COOT [41] and refined with 
BUSTER [42] in iterative cycles. Ligand restraints were 
generated with Grade [43] and Mogul [44]. The quality 
of the structures was assessed with MOLPROBITY [45]. 
Cellular assays.
The human bladder carcinoma cell line HCV29 
was obtained from Dr Richard Lamb (University of 
Liverpool, UK). This cell line has elevated mTORC1 and 
S6K activity through loss of TSC1 [46] as a result of a 
missense mutation and TSC2 loss that was confirmed by 
immunoblotting (data not shown). Cells were cultured 
in RPMI (Invitrogen, Life Technologies Ltd, Paisley, 
UK) containing 2 mmol/L glutamine (Invitrogen), 
and supplemented with non-essential amino acids 
(Invitrogen) 10% fetal bovine serum (PAA Laboratories 
Ltd, Yeovil, UK) in 5% CO2 in air at 37 °C. GI50 values 
(concentrations) causing 50% inhibition of proliferation 
for tumour cells were determined using a sulforhodamine 
B assay. Electrochemiluminescent immunoassays (Meso 
Scale Discovery, Rockville, MD, USA) measuring the 
inhibition of phosphorylation of RPS6-ser235/236, AKT-
Thr308, AKT-Ser473, GSK3b-Ser9 and S6K-Ser421/424 
were carried out as described in Raynaud et al. [47].
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